Many different cell stress pathways converge on p53 to induce a number of distinct cell biological responses such as G1 or G2 arrest, senescence or apoptosis. One of the outstanding questions with regard to p53 is how the cells can differentiate between different stresses so that p53 activation leads to the correct response. It has been known for some time that the p53 gene expresses isoforms that carry unique domains and properties, and more recent works have started to reveal some of their functions. The alternative mRNA translation product p53/47, which lacks the first 40 codons, including the first of p53's two trans-activation domains, is being linked to endoplasmic reticulum stress and the unfolded protein response to which it causes a specific G2 arrest. On the other hand, p53 itself induces G1 arrest and has no effect on the G2. The two isoforms D133p53, which lacks the first 133 amino acids, and p53b, which carries an alternative C-terminus, are derived from alternative promoter usage or splicing, respectively, and are together implied in controlling cellular senescence. Hence, through different mechanisms of gene expression control, alternative levels of p53 isoforms help the cell to differentiate between p53 activation and the response to diverse stresses. This holds promise to a better understanding of how upstream and downstream p53 pathways have evolved relative to specific p53 domains.
Introduction
The activation of the p53 tumour suppressor in response to a variety of different types of stresses and damages leads to changes in the expression of a large number of gene products that have the capacity to control a variety of different cellular functions, such as apoptosis, cell cycle arrest, senescence, DNA repair or metabolism ( Figure 1 ) (Vogelstein et al., 2000; Levine and Oren, 2009 ). However, despite this, it has remained an enigma as to how the cells distinguish between the different types of upstream p53 activation pathways so that downstream pathways trigger a suitable cellular response (Vousden and Prives, 2009) . The answers to this question have so far eluded p53 research and are certain to be complex and involve both tissue-and stressdependent regulatory factors, but, when finally clarified, will greatly enhance our understanding as to why, indeed, p53 has such an important role in controlling tumour cell development. This will give a more differentiated view on p53 activity in terms of cell and tissue effects in response to specific cellular stresses and damages, which will be important for predicting the outcome of therapies aimed at modifying p53 pathways. The recent unravelling of specific cell biological effects linked to some of the p53 isoforms holds promise to offer some help to answer these questions ( Figure 1 ). As these forms express truncated p53 proteins, their special cell biological effects will also help to understand the relationship between the domains of p53, their individual activity and the cell biological effects of p53 activation. The p53 family members p63 and p73 also express isoforms, but these will not be discussed here (Moll and Slade, 2004) .
p53/47 and G2 cell cycle arrest p53/47, or NDp53 as it also been named, was the first reported human isoform and it is derived through alternative translation initiation of the p53 mRNA at the second in-frame AUG codon (Courtois et al., 2002; Yin et al., 2002) . This renders a p53 product that lacks the first 40 amino acids of the N-terminus, including the binding site for Mdm2, which is within the highly conserved BoxI and the first of the two trans-activation domains. In fact, p53/47 was discovered due to the fact Mdm2 can promote the initiation of translation of both p53 and p53/47, but only targets the former for degradation (Yin et al., 2002) . Later work showed that translation initiation of p53 and p53/47 can be controlled by separate and, to some extent, competing mechanisms of translation, so that suppression of capdependent translation of p53 results in an increase in the synthesis of p53/47 (Candeias et al., 2006) . Insertion of an open-reading frame followed by a hairpin structure in the 5 0 -untranslated region of p53 resulted in an increase in p53/47 synthesis and a decrease in p53, indicating that cap-independent mechanisms of initiation control p53/47 translation via an internal ribosome entry site (IRES) structure located in the region of þ 1 to þ 120 of p53. Hence, the coding region of p53 serves as IRES for p53/47 (Candeias et al., 2006; Ray et al., 2006; Grover et al., 2009 ). It has also been shown that p53/47 could be generated by alternative splicing (Ghosh et al., 2004) , but it should be a rare event as the full-length p53 mRNA was evident after 20 quantitative PCR cycles, whereas the p53/47 message required 40 quantitative PCR cycles, which represents approximately 2 Â 10 20 times less amount of p53/47 mRNA. Interestingly, cap-independent expression of p53/47 from a bicistronic construct, as well as endogenous p53/ 47, was shown to be enhanced after cells had been exposed to thapsigargin or tunicamycin for longer time periods. Both compounds induce stress to the endoplasmic reticulum (ER) and trigger the unfolded protein response (UPR) (Schroder and Kaufman, 2005) . Thapsigargin affects calcium flux between ER and the cytoplasm, whereas the latter targets protein glycosylation (Kim et al., 2008) . A more physiological relevant trigger of the UPR, especially with regard to a stress response factor such as p53, is hypoxia and the ischaemic conditions that prevail in the poorly vascularized areas of solid tumours (Koumenis et al., 2002) . These, together with the high load of mutated proteins in tumour cells, have lead to the suggestion that the UPR and associated pathways have an important role in tumour development (Fernandez et al., 2000) . The UPR is also linked to cancer because of its role in both the development of resistance to chemotherapy and the sensitization of tumour cells to chemotherapy after prolonged ER stress (Ledoux et al., 2003; Mandic et al., 2003) . In order for the cell to rid itself of a potentially harmful accumulation of unfolded proteins, a series of events take place to restore the balance between newly synthesized and mature proteins. This includes induction of ER chaperones to assist protein folding, lipases to expand the ER membrane, endoplasmic reticulumassociated protein degradation to promote degradation of unfolded protein and the suppression of protein synthesis. The coordinated expression of repair factors on the level of transcription is orchestrated by ATF6 and IRE1, which are released from BiP and calrecticulin at the ER membrane upon accumulation of unfolded proteins (Urano et al., 2000; Yoshida et al., 2001; Chen et al., 2002; Lee et al., 2002; Shen et al., 2002) . The protein kinase receptor-like ER kinase (PERK) kinase is also an ER stress transducer and contributes to the UPR by a general suppression of protein synthesis by phosphorylation of the eIF2a translation initiation factor and by a selective synthesis of certain response factors (Harding et al., 1999; Ron and Walter, 2007) . The fact that p53/47 was shown to be synthesized by an alternative and regulated mechanism of translation gave the first indication that it might have a functional role in Ub TAI TAII PxxP DNA binding OD CTR Figure 1 Different types of cell stress and damage pathways converge on p53, which leads to trans-activation of a large number of gene products that can induce apoptosis, cell cycle arrest in G1 or G2 or cellular senescence. Only a few selected p53-regulated gene products that appear in the main text are mentioned here. p53 isoforms that lack different domains of p53 have been described more recently. p53b carries an alternative C-terminus sequence that lacks most of the oligomerization domain (OD) and the C-terminal regulatory domain (CTR) and is derived from alternative splicing. p53/47 comes from alternative mRNA translation and lacks the first trans-activation domain (TAI) and the binding site for the p53 regulatory factor Mdm2. D133p53 lacks the first 133 amino acids, including both TAs and the poly-proline-rich domain (PxxP), and is derived from alternative promoter usage. All isoforms have an intact DNA-binding domain.
p53 isoforms gain functions V Olivares-Illana and R Fåhraeus the p53 response (Candeias et al., 2006) . Further work showed that suppression of PERK activity, through overexpression of either a dominant-negative PERK or small interfering RNA, resulted in the suppression of p53/47 expression, indicating that PERK is the signal transducer between the ER and p53/47 expression ( Figure 2 ) (Bourougaa et al., 2010) .
Out of the many physiological responses attributed to p53 activation, cell cycle control and apoptosis are the most well studied. Upregulation of p21 CDKN1A/Cip1 is a classic p53 response factor, and in response to DNA damage, it mediates cell cycle arrest in the G1/S phase due to suppression of cyclin D-and E-dependent kinase activities (el-Deiry et al., 1993) . However, p53/47 lacks the TA1 domain required to induce p21 CDKN1A/Cip1 and it is, in fact, a potent suppressor of p53-dependent p21 CDKN1A/Cip1 expression. Thus, it has the capacity to prevent a G1/S cell cycle arrest (Courtois et al., 2002) . However, p53 activation also leads to a G2/M arrest. This is mediated by induction of 14-3-3s, which sequesters the CDC25 phosphatase in the cytoplasm, preventing the activation of the cyclin B-cyclin-dependent kinase (CDK1) complex and entry into mitosis (Hermeking et al., 1997; Peng et al., 1997; Chan et al., 1999; Hermeking and Benzinger, 2006) . New data show that that ER stress causes a G2/M arrest that is dependent on the capacity of PERK to induce the expression of p53/47, which subsequently trans-activates 14-3-3s (Figure 2) . The suppression of PERK activity, 14-3-3s expression or deletion of the ER stress response IRES of p53/47 all result in an inhibition of UPR-induced G2/ M arrest. Together, this suggests that although p53/47 activates 14-3-3s, it also suppresses the induction of p21 CDKN1A/Cip1 and, thus, prevents the cells from arresting in G1/S while favouring a G2/M block (Bourougaa et al., 2010) . In addition, expression of full-length p53 (p53FL) alone does not induce G2 arrest, but induces only GI arrest. One can only speculate at this stage why the cells favour a G2 arrest in response to ER stress. However, it has been shown that during the G2, capindependent translation is the more preferred mechanism of translation initiation (Pyronnet et al., 2000; Sivan and Elroy-Stein, 2008) . Hence, as the cell tries to reverse the accumulation of misfolded proteins by slowing down protein synthesis via the PERK pathway, the placement of the cell in the G2 via p53/47 will further help to Stress to the endoplasmic reticulum (ER) leads to an accumulation of unfolded proteins within the ER. This activates the unfolded protein response (UPR), including ATF6, IRE1 and PERK. The activation of ATF6 and IRE1 leads to trans-activation of stress response factors that promotes ER repair. PERK suppresses cap-dependent mRNA translation regulation in general via phosphorylation of eIF2a, but promotes synthesis of specific stress response proteins such as p53/47. p53/47 binds to the 14-3-3s promoter and induces synthesis of 14-3-3s, which targets cdc25, and thereby prevents the activation of the cyclin B/CDK1 complex, which results in a G2/M arrest.
p53 isoforms gain functions V Olivares-Illana and R Fåhraeus suppress cap-dependent translation, but will also allow cap-independent translation to take place in a selected number of mRNAs, such as ATF4 and cat-1, and IREScarrying mRNAs, such as p58 PITSLRE (Cornelis et al., 2000; Fernandez et al., 2002; Vattem and Wek, 2004) . Interestingly, the latter shows similarities in mRNA translation control to p53 and p53/47 as the IRES of p58 PITSLRE is within the coding sequence of p110 PITSLRE . Similar to p53/47, p58 PITSLRE is also linked to G2/M progression. It is, thus, plausible that placing the cells in G2 has an active role in the UPR. Using a similar model, it has been proposed that the induction of G1 arrest by p53 following DNA damage serves to place the cell in a more favourable position for carrying out DNA repair before entering DNA replication.
p53 isoforms unravel p53 functional domains
Both p53FL and p53/47 have the capacity to induce apoptosis, and previous studies have shown that even though the relative amount of each isoform will lead to differences in the expression of several pro-apoptotic p53 target genes such as Noxa and PUMA, the actual difference in induction of apoptosis between the two forms is small, at least under the conditions that have been tested so far (Zhu et al., 1998; Yin et al., 2002; Powell et al., 2008) . This would indicate that the information required for p53 to induce apoptosis as well as G2 arrest is harboured within the TAII domain and that the capacity to control the G1 phase of the cell cycle lies within TAI. It will be interesting to dissect p53/47 further to observe whether it is possible to lose the G2 arrest while retaining the capacity to promote apoptosis in order to test to what extent different domains of p53 that are linked to certain cell functions have evolved separately. With some more detailed information on the location and composition of the different trans-active sequences, it might be possible to compare conserved functions between species and, via this route, predict the original p53 activity that once initiated its function as a tumour suppressor.
The TAI contains the BoxI domain, which is the most conserved part of this region of p53, which might indicate that the activity of this domain, such as G1 arrest, is fundamental for the evolution of p53 (Lane et al., 2010) . However, as BoxI also forms the binding site for Mdm2 and its close homologue MdmX, and as the binding of Mdm2 to p53 appears early on in evolution, these types of predictions are difficult. As Mdm2 is a key regulator of p53 Mdm2, other interacting partners and functions are many times overlooked and it is not known to what extent the interaction between Box1 and Mdm2 affects other Mdm2-binding proteins such as pRB, p14Arf and ribosomal factors, to mention just some, and their associated cell biological functions (Marechal et al., 1994; Xiao et al., 1995; Pomerantz et al., 1998) . Furthermore, it cannot be taken for granted that the BoxI region is conserved just to preserve p53 activity or facilitate regulation by Mdm2; it is equally possible that it is the other way around-it is required to control the function of p53-binding proteins. More recent work has also shown that the RNA sequence that encodes the Box1 also has regulatory capacity on Mdm2 activity . Several studies have also found that deletion of the N-terminus of p53 promotes p53 oligomerization and this is another aspect of the TAI domain that needs to be taken into consideration (Hansen et al., 1998; Powell et al., 2008; Rajagopalan et al., 2008) . Another point relating to the dissection of p53 domains and p53 functions is that the induction of certain genes might require the consorted action of both TAI and TAII. For example, the induction of PUMA was found to be high after expression of p53wt mRNA, which gives rise to p53FL and p53/47 proteins, whereas neither p53FL nor p53/47 alone could induce the same levels .
This relates to a more general aspect of p53 domains vs p53 activity. Although it has been known, even before the identification of p53/47, that p53 harbours more than one trans-active domain (Zhu et al., 1998) , it is still often regarded in the literature that p53 has only one domain. As a consequence, the effect of a certain p53 mutation, p53-binding proteins or stress pathways are evaluated on the induction of one target gene or a few target genes only. This information is then used to represent p53 activity in general when, in fact, p53 activation can involve the altered expression of over several hundred genes. As one of the most common reporter genes is p21 CDKN1A/Cip1 , or reporter constructs carrying tandem copies of the p21 CDKN1A/Cip1 promoter, the general view of p53 trans-activity is to some extent based on a limited number of possible trans-activation events.
p53b, D133p53 and cellular senescence Cellular senescence is characterized by an irreversible stop in proliferation while the cell retains its metabolism. In addition to the first reported cellular senescence imposed by extensive proliferation and telomere shortening in human fibroblasts, it has become increasingly clear that genetic alterations and cellular stresses or damages linked to cancer development also trigger senescence. Animal models have suggested that preventing senescence can promote more malignant tumour progression and cells carrying characteristics of senescent cells can be found in pre-malignant samples that are lost as the state of transformation of the tumour cells increases (Braig et al., 2005; Collado et al., 2005; Dankort et al., 2007) .
Genotoxic drugs that induce tumour regression also induce senescence and there is a potential link between the effects of such treatments and the capacity of tumour cells to respond with a senescence programme (Efeyan et al., 2007) . Broadly, DNA damage can promote senescence via the p53 and the Rb pathways, whereas a continued activation of the H-Ras pathway and p38MAPkinase promotes senescence via p16 INC4A (Adams, 2009 ). Both p16
INC4A -and the p53-induced p53 isoforms gain functions V Olivares-Illana and R Fåhraeus p21 CDKN1A/Cip1 are, however, downstream effectors to a wide variety of stress pathways that merge on pRb through the suppression of cyclin/CDK activity (Bartkova et al., 2006; Feldser and Greider, 2007) . The details of how these and other pathways lead to the activation of senescence are now beginning to emerge (d'Adda di Fagagna et al., 2003; Adams, 2009; Collado and Serrano, 2010) . More recently, non-coding microRNAs that can silence gene expression by targeting transcription or mRNA translation have also emerged as mediators of senescence control. The p53-induced miR-34 family targets cell cycle regulatory factors, including CDK4 and cyclin E, and thereby prevents cell cycle progression and promotes senescence (He et al., 2007) .
However, how p53 activation under certain conditions can specifically result in senescence was not clear until recent work began to shed light on this decisionmaking process and implicate a role for p53 isoforms (Bourdon et al., 2005; Fujita et al., 2009) . Studies on human fibroblast lines showed an increase in p53b and a concomitant reduction in D133p53 expression levels as the cells neared a senescence passage number, but at levels below those of p53 itself. Interestingly, these changes in expression of the isoform levels are not induced by changes in either oncogene-or telomereinduced senescence. D133p53 lacks the entire transactivation domain, and, consistent with a role for D133p53 as an inhibitor of p53 activity, suppression of D133p53 leads to an induction of the p53 target genes p21
, miR-34a and Mdm2, but not PUMA or Noxa, which also results in the early induction of senescence in human fibroblasts. The levels of D133p53 correspond to the expression levels of endogenous miR34a and senescence, but have limited effect on the p53-dependent miR-34a promoter activity (Figure 3 ). Hence, it is possible that the effect of D133p53 is not on the expected p53 transcription activity, indicating that the effect of D133p53 is not restricted to act directly via p53 only. This can perhaps also help to explain how relatively low levels of D133p53 in early passage cells can completely dominate p53 activity on some target genes, but have no effect on others. On the other hand, p53b, which carries the N-termini trans-activation domains I and II or p53, is sufficient to induce p21 CDKN1A/Cip1 and Mdm2, and senescence in the presence of p53. However, interestingly, it has no effect on miR34a levels (Figure 3) . Thus, the effects of the p53b and D133p53 isoforms on senescence in human fibroblasts are likely to depend both on a direct control of p53 activity as well on indirect effects. Together, their combined effects would increase the levels of miR-34a and p21
CDKN1A/Cip1 as cells enter senescence. However, questions remain on the mechanisms of action of these isoforms on the induction of senescence, as overexpression of p53b or knockdown of D133p53 does not reflect miR-34a levels. Another question is to see how the cells control the expression of these isoforms as well as how relatively small amounts can control p53 activity. Perhaps, a mechanism similar to that for p53/47 also exists for D133p53 and p53b, in which signalling pathways selectively control the function of one, or the other, isoform. p21 CDKN1A/Cip1 p53 gene Figure 3 D133p53 is initiated from an alternative promoter (P2), and, together with the p53b splice variant that carries an alternative shorter C-terminus, these isoforms control cellular senescence. D133p53 lacks the trans-activating domains of p53 and suppresses p53 trans-activity, and the expression of pro-senescence factors p21
CDKN1A/Cip1 and miR-34a. p21 CDKN1A/Cip1 binds to and inactivates the G1/S cyclin-CDK complexes, whereas miR-34a targets cyclin E and CDK4 expression. On the other hand, p53b cooperates with full-length p53 to promote p21 CDKN1A/Cip1 expression. The combined effect of more p53b and less D133p53 is associated with the induction of replicative senescence.
Consistent with a role of p53 isoforms in the control of senescence in tumours are the observations that the levels of D133p53 are inversely correlated with the malignant grade of colon adenomas, whereas the opposite is the case for p53b. This phenotype is restricted to tumours expressing wild-type p53 and was not observed in tumours expressing mutant p53, indicating that p53 activity itself might be linked to the expression of the isoforms. However, the surrounding tissue of adenoma tumours that tested positive for b-Gal and p16
INC4A also showed an increase in the levels of p53b, but not a reduced level of D133p53, indicating that the expression regulation of the isoforms is independent.
The reason for the increase in p53b in normal tissue surrounding adenoma cells is not clear, but senescence secretome containing a complex mix of growth factors and immune regulators, such as cytokines and chemokines, are known to be secreted from senescence cells to its neighbours and to be under the regulation of the nuclear factor-kB pathway (Adams, 2009) . The role of the secretome in tumour suppression is not clear, as both growth-suppressive factors and matrix metalloproteases that can assist in extracellular breakdown and tumour spreading are included. However, a physiological role for triggering senescence in adjacent tissue is not clear, but it is interesting to note that the secretome can help to trigger an innate immune response and, as such, provide an active part of the tumour suppressor phenotype.
Finally, the alternative expression of p53 isoforms and their link to distinct cell biological effects is a good example of how alternative mechanisms of gene expression control, such as alternative promoter usage, alternative splicing or alternative mRNA translation initiation, have been developed to diversify and differentiate the activity of a gene to optimize its potential use. This concept is widely applied in the extended p53 family, from which three genes express a potential of 50 isoforms, including nine possible isoforms for p53, six for p63 and 35 for p73 (Rosenbluth and Pietenpol, 2008) . Thus, the p53, p63 and p73 genes share similar organization, which can each provide a large spectrum of active isoforms with their own unique functions.
Prospective
One of the outstanding questions with regard to p53 isoforms is how relatively small amounts can be dominant over the p53FL. A second issue that relates to p53b and D133p53 is the mechanisms of expression control. If the regulation of splicing and promoter usage can be defined, it will allow the identification of the factors that ultimately control p53-dependent control of senescence processes and the implicated regulatory pathways to be determined. In terms of understanding how different p53 functions and cell biological effects have evolved, this would make an interesting addition. In the case of p53/47, it is clear that PERK has a central role in ER stress-dependent regulation of expression, but the exact underlying mechanisms are not yet known. The link between G2 arrest and ER repair is another area that is yet a speculation, but this needs to be further studied and the model tested. As certain mRNAs are involved in controlling the G2/M progression, it is possible that a coherent translation programme is in place to execute the expression of G2/M regulatory factors. Finally, the sequencing of new species has identified p53 and Mdm2 in more primitive organisms and rekindled the interest in p53 development, and this holds promise to add to our understanding of p53 functions and of how these have developed in relation to upstream activation and downstream execution pathways, and hopefully the continued study of the mechanisms of action of p53 isoforms will add further help to this quest.
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